Clinical Trials
26 trialsNCT06502691 2026-05-19
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
University of Washington
Phase 1/2 Recruiting
NCT06819735 2026-05-06
DOMISOL
Domain Therapeutics SA
Phase 1/2 Recruiting
NCT06710847 2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT07282184 2025-12-18
Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
Tongji Hospital
Phase 1/2 Recruiting
NCT05013450 2025-12-17
Dupilumab_Metastatic NSCLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Active not recruiting
NCT04631601 2025-10-07
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Amgen
Phase 1/2 Terminated
NCT04954599 2025-10-07
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Phase 1/2 Recruiting
NCT03425279 2025-09-23
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
BioAtla, Inc.
Phase 1/2 Completed
NCT05806385 2025-09-09
LOGIC
Texas Tech University Health Sciences Center
Phase 1/2 Not yet recruiting
NCT05497453 2025-02-03
MYCHELANGELO I
Omega Therapeutics
Phase 1/2 Terminated
NCT05937438 2025-01-29
Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
Anhui Provincial Hospital
Phase 1/2 Recruiting
NCT03504488 2025-01-15
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
BioAtla, Inc.
Phase 1/2 Completed
NCT04020185 2024-12-11
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
ImmuneSensor Therapeutics Inc.
Phase 1/2 Completed
NCT03879512 2024-09-19
Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG
Wuerzburg University Hospital
Phase 1/2 Completed
NCT04721223 2024-09-19
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2 Completed
NCT05716295 2024-05-08
ORCHID-1
Medikine, Inc.
Phase 1/2 Terminated
NCT06074029 2024-02-08
Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT04193293 2023-09-21
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
SecuraBio
Phase 1/2 Terminated
NCT06022692 2023-09-05
HEAIS001
Zhejiang Hospital
Phase 1/2 Completed
NCT04639245 2023-08-03
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT05777707 2023-03-21
Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma
Beijing Friendship Hospital
Phase 1/2 Unknown
NCT05325684 2022-04-13
PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer
The Affiliated Hospital of Qingdao University
Phase 1/2 Unknown
NCT04110093 2020-12-30
Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
Shanghai Changzheng Hospital
Phase 1/2 Unknown
NCT03989310 2020-12-23
An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT04004234 2019-07-09
A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT03311789 2017-10-17
Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs
Chinese PLA General Hospital
Phase 1/2 Unknown